145
Views
2
CrossRef citations to date
0
Altmetric
Research Article

Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses

, , , , , , , , , , , & show all
Pages 912-922 | Published online: 10 Nov 2009
 

Abstract

Background aims

Monitoring cellular immune responses is one prerequisite for the rational development of cancer vaccines.

Methods

We describe an extensive effort to optimize and validate quantitatively an in vitro T-cell culture method by determining the phenotype and function of both CD4+ and CD8+ T cells, including measurement of the phenotype markers CCR7, CD45RA, CD28 and CD27 and the functional markers interferon (IFN)-γ, interleukin (IL)-2, macrophage inflammatory protein (MIP)-1β, tumor necrosis factor (TNF)-α and CD107a.

Results

Autologous peripheral blood mononuclear cells (PBMC) were potent stimulators that expanded antigen (Ag)-specific CD8+ T cells during short-term culture with the addition of IL-2 and IL-15 cytokines. Polyfunctional Ag-specific CD4+ and CD8+ T cells were detectable using this method.

Conclusions

Our culture system represents a robust human T-cell culture protocol that permits phenotypic, quantitative and qualitative evaluation of vaccine-induced CD4+ and CD8+ T-cell responses.

Acknowledgments

We thank Dr M. Roederer for providing the SPICE software, Dr Immanuel Luescher from the Tetramer Core, Lausanne Branch, Ludwig Institute of Cancer Research, for providing all the tetramers used in these experiments, Dr Bo Dupont and Alice Yeh from his laboratory for performing HLA analysis on one patient, and Dr. Miguel Perales, who provided editorial advice. This work was supported by Swim Across America, the Experimental Therapeutics Center of MSKCC and Ludwig Foundation. J. D. Wolchok was supported by a Damon Runyon-Lilly Clinical Investigator Award.

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.